The Minnesota Society of Clinical Oncology convened some of the most well-regarded experts to share cutting-edge information, including implications of molecular testing on HER2+/HER2- breast cancer, sentinel node biopsies post neoadjuvant therapy, as well as groundbreaking research findings on the use of immunotherapy for acute lymphocytic leukemia as presented by our Hematology/Oncology Fellow and Resident Recognition Award recipient.
This event was hosted by the Minnesota Society of Clinical Oncology—a Chapter Member of the Association of Community Cancer Centers.
Continuing Education:
This educational activity is jointly provided by AXIS Medical Education and the Minnesota Society of Clinical Oncology (MSCO).
This activity is intended for all members of the interprofessional cancer care team including physicians, nurses, nurse practitioners, pharmacists, physician assistants, managers, billers/coders, and social workers.
This educational activity provides updated information on the management of breast cancer, particularly advances in surgical treatment for breast cancer and new options in the treatment of hormone receptor-positive breast cancer. Participants will review emerging evidence and changes in practice that can inform the delivery of optimal care for their patients. The activity is of interest to all members of the cancer care team who are interested in learning about current advances in breast cancer research and patient care.
At the end of this educational activity, participants should be able to:
Agenda | |
---|---|
6:00 PM | Welcome and Introductions Samith Kochuparambil, MD President, Minnesota Society of Clinical Oncology |
6:05 PM | Emerging Concepts in the Surgical Management of Breast Cancer Kelly K. Hunt, MD University of Texas MD Anderson Cancer Center |
6:50 PM | Outstanding Fellow Presentation University of Minnesota |
7:00 PM | State-of-the-Art Management of Stage I-III Hormone Receptor-Positive Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute |
7:45 PM | Closing Remarks |
In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Minnesota Society of Clinical Oncology (MSCO). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
Credit Designation for Physicians AXIS Medical Education designates this activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Nursing AXIS Medical Education designates this continuing nursing education activity for 1.5 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
AXIS Contact Information For information about the accreditation of this program please contact AXIS at info@axismeded.org.
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:
Name of Faculty or Presenter/Planner | Reported Financial Relationship |
---|---|
Kelly K. Hunt, MD | Research Grants: CairnSurgical, Inc.; Eli Lilly and Company; Lumicell, Inc.; and OncoNano Medicine, Inc. Advisory Board: Armada and Merck & Co. |
Eric P. Winer, MD | Consultant: Athenex; Carrick Therapeutics; G1 Therapeutics; Genentech/Roche; Genomic Health; Gilead Sciences, Inc; GlaxoSmithKline; Jounce Therapeutics, Inc; Leap Therapeutics; Lilly USA; Novartis Pharmaceuticals Corp; Seattle Genetics, Inc; Syros Pharmaceuticals, Inc; and Zymeworks, Inc. Contracted Research: Genentech /Roche. |
The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:
Name of Planner/Manager/Reviewer | Reported Financial Relationship |
---|---|
Marilyn Haas, PhD, RN, CNS, ANP-BC | Nothing to disclose |
Balkrishna Jahagirdar, MD | Nothing to disclose |
Samith Kochuparambil, MD | Nothing to disclose |
Dee Morgillo, MEd., MT (ASCP) CHCP | Nothing to disclose |
Nicole Rodin | Nothing to disclose |
Ronald Viggiani, MD | Nothing to disclose |
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation and Request for Credit
As part of its Outstanding Hematology/Oncology Fellow and Resident Recognition Competition, the Minnesota Society of Clinical Oncology is pleased to share the research findings of its 2021 winning poster presentations.
Click here to see the posters.
You must have a State Society or ACCC account to register for this event, which will enable you to register for future events and courses with just one click.
If You DO NOT Have an Account:
State Society and ACCC Members:
Non-members:
If You Have an Account:
PRO TIP: If you save your password to your computer and remain logged in, you can register for additional events and courses in a matter of seconds—with just one click!
For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer users may experience difficulties accessing the event.
*If you are employed by a pharmaceutical/device manufacturer, consulting, or technology company, please contact April Gascon for registration information.
Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this event. For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.
Bristol Myers Squibb • Explore BMS Virtual Booth! • BMS Access Support • Learn About I-O Combination Treatment Options | Rigel Pharmaceuticals • TAVALISSE • Patient Website • BJH Publication • TAVALISSE Resources |
Beigene • Brukinsa (zanubrutinib) | Exelixis • Cabometyx • Full Prescribing Information • Access Services |
G1 Therapeutics • Cosela website • G1 to One HCP Brochure • G1 to One Patient Brochure • Patient website | Incyte • Incyte |
Merck • Merck | Pfizer • Breast Cancer • Pfizer Oncology • Pfizer Oncology Together • This is Living with Cancer |
Abbvie • Venclexta | AstraZeneca • CALQUENCE® (acalabrutinib) US HCP Website • LYNPARZA® (olaparib) US HCP Website • ENHERTU® (fam-trastuzumab deruxtecan-nxki) US HCP Website - Click to see complete Prescribing Information | |
Daiichi Sankyo • Daiichi Sankyo | Genentech
• Genentech Access Solutions | |
Lilly • Verzenio • Retevmo • Cyramza | Natera • Signatera • Altera | |
Novartis • Novartis Corporate Website • PIQRAY® (alpelisib) HR+/HER2- Advanced Breast Cancer Treatment | HCP • KISQALI® (ribociclib) Treatment: HR+/HER2- mBC | HCP | Oncopeptides • Pepaxto • On Course with Oncopeptides • U.S. Press Release | |
Pharmacyclics • IMBRUVICA® (Ibrutinib) Clinical Information 1 • IMBRUVICA® (Ibrutinib) Prescribing Information • IMBRUVICA® (Ibrutinib) Patient Support Information | Regeneron
• LIBTAYO® • Regeneron | |
Sanofi • Sanofi | Takeda • Ninlaro • Alunbrig • Iclusig |